Treatment of Stiff Person Syndrome When Rituximab Has Not Achieved Independent Walking

In patients with disabling, rapidly progressive Stiff Person Syndrome who did not achieve the expected clinical milestones on a prior line of immunotherapy, escalation to a more intensive strategy is indicated. This protocol defines that next step.

Previous Therapy — Failure Condition

The preceding line used Rituximab. The required targets — clinical improvement within the first six months, including the ability to walk independently — were not met. This absence of adequate response is the trigger for escalation to the current protocol.

Next-Line Approach (Partial Overview)

For refractory, disabling, rapidly progressive Stiff Person Syndrome in which all prior therapies have failed to provide sufficient benefit, this protocol involves autologous hematopoietic stem-cell transplantation — an intensive cellular rescue strategy. The complete conditioning approach, sequencing, and patient-selection criteria are detailed in the full protocol.

Clinical Goal

✓ Improved ambulation and ability to perform physical tasks.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1212/NXI.0000000000200109

Autologous hematopoietic stem-cell transplantation (for a disabling, rapidly progressive disease, if all therapies failed to provide sufficient benefits)

In one study, 3 patients with SPS and 1 with progressive encephalomyelitis with rigidity and myoclonus who received auto-HSCT preceded by cyclophosphamide 2 g/m2, granulocyte colony-stimulating factor, and antithymocyte globulin exhibited improved ambulation and ability to perform physical tasks; one wheelchair-bound patient became able to walk with a walker.

View source ↗